Development of an In-Vitro Angiogenesis System

Information

  • Research Project
  • 7118996
  • ApplicationId
    7118996
  • Core Project Number
    R21HL081152
  • Full Project Number
    5R21HL081152-02
  • Serial Number
    81152
  • FOA Number
    PA-03-58
  • Sub Project Id
  • Project Start Date
    9/5/2005 - 19 years ago
  • Project End Date
    8/31/2007 - 17 years ago
  • Program Officer Name
    LUNDBERG, MARTHA
  • Budget Start Date
    9/1/2006 - 18 years ago
  • Budget End Date
    8/31/2007 - 17 years ago
  • Fiscal Year
    2006
  • Support Year
    2
  • Suffix
  • Award Notice Date
    8/29/2006 - 18 years ago
Organizations

Development of an In-Vitro Angiogenesis System

DESCRIPTION (provided by applicant): Disregulation of vascular growth (angiogenesis) underlies many diseases that include cancer, diabetes, and arthritis. Existing models of angiogenesis in vitro are important experimental tools, but do not reproduce in vivo-like angiogenesis from a "parent" vessel filled with flowing blood. We propose to develop an advanced model of angiogenesis in vitro comprised of tissue-engineered bioartificial microvessels (BMVs) containing flowing luminal fluid and sprouting endothelial cell (EC) capillaries into a supportive gel of extracellular matrix. BMVs will be constructed by culture of ECs around a micro-diameter mandrel whose ends fit closely into polymer micro-tubing. Extraction of the mandrel leaves a tube of ECs which is perfused with nutritive media. Aim 1 evaluates the influence of BMV diameter and rate of luminal flow on sprout formation. Also, composite BMVs (ECs surrounded with vascular smooth muscle cells [SMCs]) will be generated. We hypothesize that a proportion of EC capillaries from composite BMVs will be reinforced by SMCs to form artery- or vein-like conducting vessels. In Aim 2, two adjacent BMVs will be induced to sprout a network of interconnected capillaries. We propose that induction of a pressure gradient between the BMVs will cause fluid to flow between the BMVs via the capillary network, simulating a capillary bed in vivo with arterial and venous connections. We believe our novel model will have a major impact on angiogenesis research and treatment of important angiogenesis-mediated diseases. Moreover, the model has a significant potential to be translated into microvascular systems for artificial tissues and organs. We consider our research program to be ideally suited to the R21 mechanism.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R21
  • Administering IC
    HL
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    160342
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:160342\
  • Funding Mechanism
  • Study Section
    BTSS
  • Study Section Name
    Bioengineering, Technology and Surgical Sciences Study Section
  • Organization Name
    VISIONGATE, INC.
  • Organization Department
  • Organization DUNS
    158286786
  • Organization City
    GIG HARBOR
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98335
  • Organization District
    UNITED STATES